Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
In the Literature
In the Literature - March 2015
In the Literature
March 2015, Vol 6, No 2
Read Article
New Payment Model Saves Money, Maintains Outcomes
By
Kate O'Rourke
In the Literature
August 2014, Vol 5, No 6
New payment models that reward cost-effective, high-quality cancer care are needed. An experimental physician payment model that rewards physicians for focusing on best treatment practices and health outcomes rather than the widely used fee-for-service (FFS) model resulted in cost-savings, without affecting the quality of care among patients with 3 types of cancer.
Read Article
G-CSF Pathways Compliance Reduces Emergency Department Visits, Hospitalizations
Clinical Pathways
,
In the Literature
August 2014, Vol 5, No 6
Clinical pathways have been suggested as a good method to implement guidelines into clinical practice and to reduce treatment variability. Although oncology clinical pathways have been studied previously, a new study looked at supportive care services and their effect on reducing emergency department visits and hospitalizations associated with chemotherapy toxicitie.
Read Article
Interinstitutional Variations in Cancer Treatment Identified
In the Literature
August 2014, Vol 5, No 6
Little is known about why patient care varies greatly for patients with similar illnesses, such as in patients with different types of cancer. Variation in the care of patients with cancer signals a lack of consensus about what constitutes optimal care; this suggests important gaps in the evidence base in which research may have an effect. In a new study, researchers sought to systemically assess interinstitutional variation in the management decisions for 4 common cancers using the National Comprehensive Cancer Network (NCCN) Outcomes Database.
Read Article
Ibrutinib Outperforms Ofatumumab, Extends Survival in Patients with CLL
In the Literature
August 2014, Vol 5, No 6
In a head-to-head study comparing ibrutinib (Imbruvica) and ofatumumab (Arzerra) for the second-line treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), ibrutinib significantly improved progression-free survival (PFS) time, overall survival (OS), as well as response rate.
Read Article
Study Identifies Troubling Trends in NSCLC Trials
In the Literature
June 2014, Vol 5, No 5
Changes in the design and interpretation of phase 3 trials for advanced non–small-cell lung cancer (NSCLC) have begun to emerge regarding statistical power, sample size, and the primary end points used. In a new study, researchers explored how the design and interpretation of these trials has changed over the past 3 decades.
Read Article
Panitumumab and Cetuximab Show Comparable Survival Benefit in Patients with Metastatic Colorectal Cancer
In the Literature
June 2014, Vol 5, No 5
Panitumumab (Vectibix) proved noninferior to cetuximab (Erbitux) in overall survival (OS) in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC), according to the results of ASPECT (A Study of Panitumumab Efficacy and Safety Compared to Cetuximab).
Read Article
Genetic Testing to Select Targeted Therapies Increases Survival in Lung Cancer
In the Literature
June 2014, Vol 5, No 5
The identification of oncogenic drivers has helped transform the care of patients with adenocarcinoma, the most common type of lung cancer diagnosed in 130,000 patients in the United States and 1 million persons worldwide annually.
Read Article
EML4-ALK Fusion Testing and Crizotinib Are Not Cost-Effective in NSCLC
In the Literature
May 2014, Vol 5, No 4
Studies with the tyrosine kinase inhibitor crizotinib (Xalkori) have shown significant improvement in clinical outcomes for the treatment of echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase (EML4-ALK) fusion-positive non–small-cell lung cancer (NSCLC), but researchers recently questioned its cost-effectiveness.
Read Article
Chemotherapy Better Option for Patients with Lung Cancer without EGFR Mutations
In the Literature
May 2014, Vol 5, No 4
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred treatment option for patients with advanced non–small-cell lung cancer (NSCLC) who have tested positive for EGFR mutations, because of better outcomes than conventional chemotherapy.
Read Article
Page 5 of 13
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC
William King
2.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
3.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma